Items where authors include "Hoch, U"

Article

Rugo, HS, Cortes, J, Awada, A et al. (12 more authors) (2018) Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol. Clinical Cancer Research, 24 (14). pp. 3348-3357. ISSN 1078-0432

Cortés, J, Rugo, HS, Awada, A et al. (16 more authors) (2017) Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial (vol 165, pg 329, 2017). Breast Cancer Research and Treatment, 166 (1). pp. 327-328. ISSN 0167-6806

Cortés, J, Rugo, HS, Awada, A et al. (16 more authors) (2017) Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Research and Treatment, 165 (2). pp. 329-341. ISSN 0167-6806

Twelves, C, Cortés, J, Shaughnessy, JO et al. (16 more authors) (2017) Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician’s choice: Results from the randomised phase III BEACON trial. European Journal of Cancer, 76. pp. 205-215. ISSN 0959-8049

Cortés, J, Rugo, HS, Twelves, C et al. (10 more authors) (2016) Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial. SpringerPlus, 5 (1). 1033. ISSN 2193-1801

Proceedings Paper

O'Shaughnessy, J, Rugo, H, Awada, A et al. (16 more authors) (2016) Etirinotecan pegol (EP) significantly improves overall survival in patients with advanced breast cancer (aBC) and a history of brain metastases (BM). In: European Journal of Cancer. 10th European Breast Cancer Conference (EBCC-10), 09-11 Mar 2016, Amsterdam, Netherlands. Elsevier , S111-S112.